Cefotim (Cefotaxime) is an injectable antibiotic used in the management of severe bacterial infections across key body systems. Its role is applied in addressing the underlying bacterial source, helping to ease symptoms associated with acute episodes. The medication is indicated for numerous serious bacterial infections.

The medication is commonly used for conditions where bacterial infection may pose a serious concern, such as sepsis, meningitis, complicated pneumonia, intra-abdominal infections, and severe bone and joint infections. It helps address groups of symptoms that may become intense, including persistent high fever, chills, severe localized pain, and neurological signs like intense headache.

Applied in clinical settings that involve acute or unstable symptom patterns, Cefotim supports the easing of severe, localized symptoms such as respiratory distress and contributes to general well-being during symptomatic phases. It is also used in a preventative context, providing short-term prophylactic support during high-risk surgical procedures, and may assist in managing the risk of developing post-operative infections.

“This medicine is relevant when supportive symptom management is appropriate in conditions marked by increased physiological stress.”

Quick Fact: Relief for Systemic Discomfort
Cefotim assists with maintaining functional stability by addressing the source of infection, which may help ease the overall burden of symptoms associated with systemic imbalance.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Cefotim?

Cefotim (Cefotaxime) is subject to specific population eligibility rules defined in official government regulatory documents.

---

Contraindicated Populations (Must Not Use)

Contraindication
Patients with a known hypersensitivity or allergy to Cefotaxime or any other cephalosporin class of antibiotics.
Individuals with a history of cephalosporin-associated hemolytic anemia.
Patients with a known allergy to lidocaine, if the medicine is prepared with a lidocaine diluent for intramuscular administration.

---

Eligibility Restrictions and Conditional Use

Age-Related Use

Cefotim is approved for adults and children, including neonates. However, use in older adults requires caution due to the increased likelihood of age-related decreases in renal function.

Condition-Based Restrictions

Patients with markedly impaired renal function are eligible only if a special dosage regimen is applied, as standard doses may lead to excessive drug accumulation. Caution is also required for individuals with a history of lower gastrointestinal disease, particularly colitis.

Pregnancy and Lactation

Use during pregnancy (FDA Category B) is restricted and only justified if the potential benefit outweighs the possible risk. Cefotaxime is excreted in breast milk, necessitating caution for nursing mothers.

Interactions with other medicines and products

Cefotim (Cefotaxime) interacts with specific medicinal products and substances through documented pharmacokinetic and pharmacodynamic mechanisms, as outlined in official regulatory information.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration of Probenecid is a documented pharmacokinetic interaction. Probenecid interferes with the renal tubular transfer of Cefotaxime, which significantly reduces the antibiotic's clearance and results in an approximate two-fold increase in its plasma concentration. Conversely, Cefotaxime may decrease the level and effect of oral contraceptives by altering the intestinal flora, a mechanism officially described in regulatory documentation.

Restrictions and Potentiated Risks

Interaction Type	Interacting Substance(s)	Official Outcome/Restriction
Pharmacodynamic Risk	Aminoglycosides or Potent Diuretics (e.g., Furosemide)	Potentiates the risk of nephrotoxicity (kidney damage). Monitoring is advised for the elderly and patients with pre-existing renal impairment due to higher risk.
Physical Incompatibility	Aminoglycosides	Must not be mixed in the same syringe or infusion fluid.
Administration Contraindication	Lidocaine Injection BP	Use of Cefotaxime reconstituted with Lidocaine is contraindicated for intravenous administration.
Laboratory Test Interference	Direct Coombs Test, Copper Reduction Urine Glucose Tests	May cause false positive results.

Certain herbal products, such as Willow Bark and Rose Hips, may also increase Cefotaxime's systemic level via competition for renal tubular clearance.

Cefotim (Cefotaxime) functions as a highly targeted bactericidal agent by exploiting the unique enzymatic pathways of the bacterial cell.

Covalent Blockade of the Bacterial Cell Wall

This process covers the drug’s primary action on Penicillin-Binding Proteins (PBPs), a class of bacterial enzymes essential for cell structure. Cefotim acts as an irreversible inhibitor, permanently binding to and inactivating the PBPs, thereby preventing them from performing the final cross-linking step of peptidoglycan synthesis. This specific molecular targeting initiates the structural destabilization of the bacterial cell wall.

Triggering Cellular Self-Destruction (Lysis)

The structural destabilization caused by PBP inhibition initiates a destructive cellular cascade. The compromised cell structure activates the bacteria's own latent autolysins, which dismantle the cell from within, leading to rupture and death (lysis) due to internal pressure. This molecular cascade translates the initial enzyme blockade into the final physiological effect of cellular destruction.

Sustained Mechanism via Active Metabolite

Cefotim is metabolized into Desacetylcefotaxime, which is a microbiologically active compound. This metabolite shares the exact same mechanistic action—the inhibition of PBPs—providing a sustained, dual-component bactericidal capacity that contributes to the total bactericidal capacity against susceptible pathogens.

Official Administration Instructions

Cefotim (Cefotaxime) is a prescription-only injectable antibiotic that must be prepared and administered exclusively in a clinical setting by a healthcare professional. Its use is guided by detailed instructions regarding route, dosage, frequency, and patient-specific factors, all strictly defined in official product documentation.

Route and Preparation

Cefotim is intended solely for parenteral administration, meaning it is given via Intravenous (IV) injection or infusion, or by Intramuscular (IM) injection. The medicine is supplied as a lyophilized powder that must be reconstituted with a specific diluent, such as sterile water for injections, immediately before use. The IV route is generally required when the total daily dose exceeds 2 g or if frequent administration (more than twice daily) is necessary.

Standard Labeled Dosing

Adult dosing is flexible and depends on the severity of the infection. The usual regimen for less severe infections is 1 g every 12 hours. For moderate to severe infections, the dose may be increased to 1 to 2 g every 8 hours. In severe or life-threatening cases, the dose can be up to 2 g every 4 to 8 hours, with a maximum daily dose of 12 g.

Treatment duration is not fixed but is typically specified to continue for at least 3 to 4 days after symptoms have clinically subsided. For perioperative prophylaxis (preventative use), a single dose of 1 to 2 g is given 30 to 90 minutes before surgery.

Special Population Adjustments

Official instructions mandate dose reduction for patients with severely impaired renal function. For adult patients with a creatinine clearance le 5 mL/min, the maintenance dose should be reduced by half without altering the frequency of administration. Pediatric dosing is based on body weight (mg/kg/day).

Research Evidence / Overview of Studies for Cefotim

This section summarizes the structure and reported observations from the clinical research on Cefotim (Cefotaxime), adhering to descriptions published in authoritative governmental and peer-reviewed sources. It focuses solely on what the studies examined and the characteristics of the evidence, providing a neutral overview that avoids clinical advice, therapeutic recommendations, or statements of effectiveness.

---

Evidence Overview for Severe Systemic Infections

The foundational research base for Cefotim largely consists of extensive, multi-center Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time in patients with various severe, systemic conditions. This evidence base contributes to understanding symptom patterns and short-term changes in populations where there is high physiological strain or stress.

---

Research Evidence for Lower Respiratory Tract Infections and Sepsis

Research has explored Cefotim in the context of severe conditions like pneumonia and bloodstream infections, which involve temporary physiological imbalance.

For Lower Respiratory Tract Infections (such as severe pneumonia), evidence comes from RCTs and open-label trials that compared Cefotim regimens against other studied therapeutic agents. Researchers monitored outcomes related to physical discomfort and systemic imbalance, measuring the resolution of fever and general respiratory symptoms. The results apply only to the populations and resistance patterns present when the studies were conducted. Long-term pulmonary outcomes extending beyond the immediate post-treatment period are not well characterized in the evidence base.

For Sepsis and Septicemia (severe bloodstream infection), research monitored physiological strain or stress, examining outcomes such as 30-day survival rates, microbiological testing of blood cultures, and length of stay in the hospital. In research, Cefotim was frequently studied as part of a combination regimen with other antibiotics. Evidence examining Cefotim’s activity when used alone is limited in these contexts.

---

Key Uncertainties and Research Gaps

While Cefotim has an established evidence base, researchers acknowledge areas where research is insufficient:

• Multi-drug Resistance (MDR): Findings were mixed regarding its activity against certain MDR strains. Research is ongoing regarding its activity in infections caused by organisms like ESBL-producing bacteria, and certainty is limited for its use alone against these challenging threats.
• Combination Therapy: Evidence examining the independent effect of Cefotim is limited by this combination practice, which means the research mostly reflects the outcomes of the total regimen.

Key Studies & References

1. Cefotaxime: Drug Information (NIH/NLM MedlinePlus)

Common questions about Cefotim (FAQ)

Q: Is Cefotim considered a strong antibiotic?

Cefotim's active ingredient, Cefotaxime, is officially classified as a third-generation cephalosporin. This class of medicine is recognized for its broad spectrum of activity and is described in official documentation as a bactericidal agent, meaning it is designed to actively kill susceptible bacteria.

Q: How quickly does Cefotim start working after administration?

Official pharmacokinetic data indicates that Cefotaxime reaches its highest concentration in the bloodstream very rapidly following administration. The medicine begins its antibacterial action quickly, with its half-life—the time required for half the drug to be eliminated from the body—being approximately one hour.

Q: Is Cefotim effective against all types of bacteria?

Official information indicates that Cefotim is active against a specific list of susceptible bacteria. However, like other antibiotics, Cefotim is not effective against all strains, with regulatory documents noting that many isolates that produce extended-spectrum beta-lactamase (ESBL) are resistant to the drug.

Q: Does Cefotim treat severe infections only?

No. Regulatory dosing instructions cover regimens for a wide range of uses, from infections categorized as mild to moderate up to those that are severe or life-threatening. The specific infection type and severity guide the professional administering the medicine on which regimen to follow.

Q: Do you need to stop Cefotim if you develop diarrhea?

Diarrhea is a possible side effect of the medicine. Official guidance notes that if patients develop watery or bloody stools, it is important to seek immediate attention from a physician, as this can be a sign of a serious gastrointestinal condition like Pseudomembranous Colitis.

Q: What kind of studies support the use of Cefotim?

The evidence base for Cefotim includes extensive Randomized Controlled Trials (RCTs) and open-label trials. These studies were used to examine outcomes in patients with severe, systemic infections, such as lower respiratory tract infections and sepsis, and form the basis for its approved uses.

Q: How long does Cefotim typically stay in your system?

The drug’s time in the system is measured by its half-life, which is the time it takes for the concentration of the medicine to halve. Official pharmacokinetic data indicates the half-life for Cefotaxime is about one hour, and for its active metabolite, it is approximately 1.5 hours.

Q: Is feeling tired a normal side effect of Cefotim?

Official summaries of adverse effects sometimes include general disorders, such as asthenia, which means a lack of energy or strength, and malaise. These symptoms may align with the patient's general interpretation of feeling tired or unwell.

Q: Can Cefotim be used by patients with kidney issues?

Yes, Cefotim can be used by patients with kidney issues, but the official instructions are conditional. Regulatory documents mandate a reduction in the total daily dose for patients with significantly impaired kidney function to prevent excessive accumulation of the drug and its active metabolite.

Q: Is Cefotim generally considered acceptable for older patients?

While there are no specific dosage recommendations for the elderly population, official documents advise caution due to the possibility of age-related decreases in kidney function. This decrease in function may necessitate a dose adjustment.

Q: What is the information about Cefotim use in children?

Cefotim is approved for use in both children and neonates (newborns), according to official regulatory documentation. Specific dosing regimens based on body weight are defined in the product information for these younger populations.

Q: Does Cefotim treatment affect birth control pills?

Yes, regulatory documents describe a potential interaction. Official information states that Cefotaxime may decrease the level and effect of oral contraceptives by altering the natural bacteria in the intestine.

Q: What happens if a dose of Cefotim is missed?

General patient guidance indicates that a missed dose may be administered as soon as it is remembered. However, if it is close to the next scheduled administration time, the missed dose is typically advised to be skipped to maintain the regular schedule.

Q: Is Cefotim the same thing as Ceftriaxone?

No. Cefotim's active ingredient is Cefotaxime. While both Cefotaxime and Ceftriaxone are classified as third-generation cephalosporin antibiotics, they are recognized in regulatory documents as separate chemical compounds within the same drug class.

Q: How does Cefotim differ from other antibiotics like penicillin?

Cefotim is a cephalosporin, whereas penicillin is a separate type of beta-lactam antibiotic. While they share a similar mechanism of action against bacteria, their differing chemical structures result in distinct activity against various types of pathogens.

Q: Are there any long-term effects associated with Cefotim use?

Official documents note that treatment lasting longer than 10 days is associated with an increased risk of blood cell abnormalities, such as neutropenia (a low count of a specific type of white blood cell). For this reason, regulatory guidelines advise that blood counts should be monitored during extended treatment.

Q: Do studies show Cefotim causes antibiotic resistance?

Regulatory information includes a warning that using any antibacterial drug, including Cefotim, when it is not needed may increase the risk of bacteria developing resistance to the drug. This is a general principle applied to all antibiotics.

Q: Is Cefotim used for infections outside of a hospital setting?

Cefotim is an injectable, prescription-only antibiotic that must be prepared and administered exclusively by a healthcare professional. This requirement typically restricts its use to controlled clinical settings like hospitals or specialized clinics.

Q: Can Cefotim be used during pregnancy?

Official classification states that use during pregnancy is conditional and is only considered appropriate after a healthcare professional assesses the potential benefit versus the possible risk.

Q: Is it acceptable to breastfeed while receiving Cefotim?

Regulatory documents advise that caution is necessary for nursing mothers because Cefotaxime is known to be excreted into breast milk.

Q: Can Cefotim affect blood sugar levels?

Cefotim can cause interference with certain laboratory tests. Official documents warn that it may cause a false positive reaction to glucose when certain non-enzymatic methods are used for testing glucose in the urine.

Q: What is the process for monitoring a patient receiving Cefotim?

Regulatory guidelines advise that blood counts should be monitored for treatment courses lasting longer than 10 days. Additionally, renal function must be monitored when Cefotim is used alongside certain other medicines, especially those that also affect the kidneys.

Q: What is the main concern for patients with a known penicillin allergy using Cefotim?

Because Cefotim is a beta-lactam antibiotic, like penicillin, official labels describe that caution is required when the drug is administered to patients with a known history of hypersensitivity to penicillin due to a potential, though rare, risk of cross-reactivity between the two drug classes.

The official regulatory documents specify precise conditions for storing and disposing of Cefotim to maintain its stability and quality.

Storage and Handling

The unopened container or vial must be stored at controlled room temperature (e.g., typically below 30 C), and it must be protected from light by remaining in its original carton. Once the product is prepared or reconstituted, it has a limited in-use stability period. The reconstituted solution is typically stable for a specified number of hours (e.g., 8–24 hours) when stored at controlled room temperature or refrigerated (e.g., 2 C to 8 C), and must be discarded if unused within that time.

Disposal

All expired or unused medicine, including any remaining contents in the vial, should be disposed of in accordance with local regulations. To protect the environment, the product should not be disposed of via wastewater (e.g., flushed down the toilet) unless the official drug labeling explicitly instructs this method. As a general rule, keep this medicine out of the sight and reach of children.